TP53 and B-cell chronic lymphocytic leukemia: Stimulated chromosome banding analysis (CBA) has recently been included in the biological criteria for stratification of patients with chronic lymphocytic leukemia (CLL) in some guidelines [1, 2] together with immunoglobulin heavy variable (IGHV) gene mutational analysis and TP53 abnormalities, i.e., 17p13 deletion assessed by interphase fluorescence in situ hybridization (FISH) and TP53 mutation.